Literature DB >> 16885557

Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein.

Richard N Kitsis1, Ishwarlal Jialal.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16885557     DOI: 10.1056/NEJMcibr063197

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  Development of multiple complications in type 2 diabetes is associated with the increase of multiple markers of chronic inflammation.

Authors:  Jawl-Shan Hwang; Tsu-Lan Wu; S C Chou; C Ho; Pi-Yueh Chang; Kuo-Chien Tsao; Jeng-Yi Huang; Chien-Feng Sun; James T Wu
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

2.  Cardiomyocyte-targeted siRNA delivery by prostaglandin E(2)-Fas siRNA polyplexes formulated with reducible poly(amido amine) for preventing cardiomyocyte apoptosis.

Authors:  Sun Hwa Kim; Ji Hoon Jeong; Mei Ou; James W Yockman; Sung Wan Kim; David A Bull
Journal:  Biomaterials       Date:  2008-08-23       Impact factor: 12.479

3.  Value of C-reactive protein in predicting left ventricular remodelling in patients with a first ST-segment elevation myocardial infarction.

Authors:  Iwona Swiatkiewicz; Marek Kozinski; Przemyslaw Magielski; Tomasz Fabiszak; Adam Sukiennik; Eliano Pio Navarese; Grazyna Odrowaz-Sypniewska; Jacek Kubica
Journal:  Mediators Inflamm       Date:  2012-09-02       Impact factor: 4.711

4.  Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction.

Authors:  Iwona Swiatkiewicz; Marek Kozinski; Przemyslaw Magielski; Joanna Gierach; Tomasz Fabiszak; Aldona Kubica; Adam Sukiennik; Eliano Pio Navarese; Grazyna Odrowaz-Sypniewska; Jacek Kubica
Journal:  Inflamm Res       Date:  2012-03-24       Impact factor: 4.575

Review 5.  Cell death in health and disease.

Authors:  Richard A Lockshin; Zahra Zakeri
Journal:  J Cell Mol Med       Date:  2007-11-20       Impact factor: 5.310

6.  A herbal formula, SYKT, reverses doxorubicin‑induced myelosuppression and cardiotoxicity by inhibiting ROS‑mediated apoptosis.

Authors:  Ting Chen; Hong-Mei Shen; Zhi-Yong Deng; Zuo-Zhang Yang; Rui-Lian Zhao; Li Wang; Zhi-Ping Feng; Chao Liu; Wen-Hui Li; Zhi-Jie Liu
Journal:  Mol Med Rep       Date:  2017-03-01       Impact factor: 2.952

7.  Role of Ischemic Preconditioning in the Cardioprotective Mechanisms of Monomeric C-Reactive Protein-Deposited Myocardium in a Rat Model.

Authors:  Eun Na Kim; Jae-Sung Choi; Chong Jai Kim; So Ra Kim; Se Jin Oh
Journal:  J Chest Surg       Date:  2021-02-05

8.  Analysis of factors related to short-term prognosis in patients undergoing percutaneous coronary intervention for acute myocardial infarction.

Authors:  Yi Ma; Li Li; Xiao-Ming Shang; Zheng Tan; Xue-Bin Geng; Bi-Qiong Zhao; Mei-Rong Tian
Journal:  Exp Ther Med       Date:  2013-01-25       Impact factor: 2.447

Review 9.  Selective Apheresis of C-Reactive Protein for Treatment of Indications with Elevated CRP Concentrations.

Authors:  Stefan Kayser; Patrizia Brunner; Katharina Althaus; Johannes Dorst; Ahmed Sheriff
Journal:  J Clin Med       Date:  2020-09-12       Impact factor: 4.241

Review 10.  [CRP apheresis in acute myocardial infarction and COVID-19].

Authors:  Michael Buerke; Ahmed Sheriff; Christoph D Garlichs
Journal:  Med Klin Intensivmed Notfmed       Date:  2022-03-25       Impact factor: 1.552

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.